4.8 Article

Late Outcomes After Carotid Artery Stenting Versus Carotid Endarterectomy Insights From a Propensity-Matched Analysis of the Reduction of Atherothrombosis for Continued Health (REACH) Registry

Journal

CIRCULATION
Volume 122, Issue 11, Pages 1091-1100

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCULATIONAHA.109.933341

Keywords

carotid arteries; endarterectomy; prognosis; stents

Funding

  1. Sanofi-Aventis
  2. Bristol-Myers Squibb
  3. Waksman Foundation (Tokyo, Japan)
  4. Eisai
  5. Ethicon
  6. Heartscape
  7. The Medicines Co.
  8. Bayer vital
  9. Boehringer-Ingelheim
  10. Lundbeck
  11. Astellas
  12. Otsuka
  13. DaiichiSankyo
  14. Schering-Plough
  15. Schering-Plough, GlaxoSmithKline
  16. Novartis
  17. Teijin
  18. Towa-Eiyo
  19. Bayer
  20. Pfizer
  21. Banyu
  22. Mochida
  23. Johnson and Johnson
  24. Kowa
  25. Avot Vascular
  26. Tanabe Mitsubishi,
  27. Accumetrics
  28. InteKrin
  29. Merck
  30. Takeda
  31. Servier
  32. DaiichiSankyo-Lilly
  33. Medtronic
  34. Roche

Ask authors/readers for more resources

Background-In patients with carotid artery disease, carotid endarterectomy (CEA) and carotid stenting (CAS) are treatment options. Controversy exists as to the relative efficacy of the 2 techniques in preventing late events. Methods and Results-The Reduction of Atherothrombosis for Continued Health (REACH) Registry recruited >68 000 outpatients >= 45 years of age with established atherothrombotic disease or >= 3 risk factors for atherothrombosis. Patients with CAS or CEA were chosen and followed up prospectively for the occurrence of cardiovascular events. Propensity score matching was performed to assemble a cohort of patients in whom all baseline covariates would be well balanced. Primary outcome was defined as death or stroke at the 2-year follow-up. Secondary outcome was stroke or transient ischemic attack. Tertiary outcome was a composite of death, myocardial infarction, or stroke and the individual outcomes. Of the 68 236 patients with atherothrombosis, 3412 patients (5%) had a history of carotid artery revascularization (70% asymptomatic carotid stenosis), 1025 (30%) with CAS and 2387 (70%) with CEA. Propensity score analyses matched 836 CAS patients with 836 CEA patients. At the end of 2 years of follow-up, in the propensity score-matched cohort, CAS was associated with a risk similar to CEA for the primary (hazard ratio [HR], 0.85; 95% confidence interval [CI], 0.57 to 1.26), secondary (HR, 1.20; 95% CI, 0.73 to 1.96), and tertiary (HR, 0.72; 95% CI, 0.51 to 1.01) composite outcome, death (HR, 0.63; 95% CI, 0.40 to 1.00), and stroke (HR, 1.48; 95% CI, 0.79 to 2.80). Conclusion-In a real-world cohort of patients with a history of carotid artery revascularization, CAS was comparable to CEA for late outcomes. (Circulation. 2010;122:1091-1100.)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available